We are providing rapid, highly accurate COVID diagnostics to those who need it most.
In partnership with QIAGEN®, Ellume has accelerated the development of a rapid, reliable COVID test to support the global response to the coronavirus pandemic. The QIAGEN Access Anti-SARS-CoV-2 Total, is a high-performance serological test which detects antibodies in people who have been exposed to SARS-CoV-2.
The test has received an Emergency Use Authorization (EUA) from the US FDA, with CE-IVD marking anticipated in the coming weeks.
Sensitivity of 100% (CI 88.43–100.00%)
Specificity of 100% (CI 95.20–100.00%)
|● Early positive results from 3 minutes
● Simple testing process
● Minimal training requirements
● Single patient visit
● Objective automated test result
● No calibration or maintenance required
● No cold chain required
● No continuous power supply required
● No computer access required
Coronavirus: The Facts
* Last update: 20 August 2020 – https://www.who.int/emergencies/diseases/novel-coronavirus-2019